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1310.e1 The Journal of Thoracic and CaObjective: We hypothesized that implantation of adult mesenchymal stem cells after
acute myocardial infarction mobilizes bone marrow precursor cells by activating the
stem cell factor pathway, and that overdriving this pathway would enhance the
beneficial effects of cell transplantation.
Methods: After coronary ligation, medium, mesenchymal stem cells, or stem cell
factor–overproducing mesenchymal stem cells were injected into the anterior left
ventricle. Cells from -galactosidase transgenic mice enabled tracking of injected
cells. The global and local impact of the cells was evaluated by measuring cytokine
levels, endothelial progenitor cells, and myocardial angiogenesis, and by addressing
cardiomyogenesis with confocal microscopy. The impact on cardiac function was
evaluated by pressure-volume loops. Ventricular morphometrics were measured
after in situ perfusion-fixation of the hearts at physiologic pressures.
Results: Implantation of mesenchymal stem cells increased myocardial stem cell
factor levels 2.0-fold, endothelial progenitor cell mobilization 2.7-fold, and myo-
cardial angiogenesis 2.3-fold (P  .05), but did not induce mitogenesis in host
cardiomyocytes or give rise to -galactosidase–expressing cardiomyocytes. Cell-
transplanted groups had improved indices of cardiac function, including preload
recruitable stroke work and end-systolic elastance (P  .001). Cell transplantation
resulted in 2.0-fold smaller ventricular volumes (P  .001) and 2.0-fold reduced
infarct scar area (P .056), but had no effect on the volume of spared myocardium.
Stem cell factor overproduction imparted greater functional benefit without inducing
detectable histologic cardiomyocyte regeneration.
Conclusion: Mesenchymal stem cell implantation after myocardial infarction facil-
itates functional cardiac regeneration without myocyte regeneration through aug-
mentation of endogenous infarct repair, which is enhanced by stem cell factor.
Transplantation of cultured bone marrow mesenchymal stem cells (MSCs)into the infarcted anterior left ventricle (LV) improved cardiac function inboth rodent and porcine models.1,2 A subset of MSC, the multipotent adult
progenitor cell, was recently identified that can differentiate to cells of all 3 germ
layers,3 raising hopes that the MSC could form the basis of cell-based therapeutic
strategies for cardiac regeneration.4 The mechanisms of action, however, remain
unclear. The functional benefits of cell transplantation may derive from important
paracrine effects of the cells on the local remodeling process as well as the
recruitment and support of precursor cells important in tissue repair, but without the
conversion of the cells to functioning cardiomyocytes.
Most precursor cells that have been shown to improve cardiac function after
direct myocardial injection express the proto-oncogene c-kit tyrosine kinase recep-
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SCF/c-kit signaling is critical for the maintenance, function,
and activation of all c-kit– expressing cells,7 which include
hematopoietic stem cells,8 endothelial progenitor cells
(EPCs),9 and the recently identified cardiac stem cells.10
Reports of differentiation of all these c-kit cells to a
cardiomyocyte phenotype have been published6,10,11 but
remain controversial.9,12
In light of this, we hypothesized that (1) MSC transplan-
tation does not result in significant cardiomyogenesis, (2)
MSC transplantation improves cardiac function and angio-
genesis by mobilizing bone marrow-derived precursor cells
such as EPC, and (3) overexpression of SCF by MSC
further improves the beneficial effects of MSC transplanta-
tion after myocardial infarction (MI).
Methods
Mesenchymal Stem Cell Isolation and Stem Cell
Factor Transfection
Bone marrow was flushed from the femur and tibia of 1 C57Bl/6
(Charles River, Wilmington, Mass) and 1 Rosa26 (-galactosidase
transgenic, Jackson Laboratories, Bar Harbor, Maine) mice to
establish the MSC lines as described.1 After 10 passages the cells
expressed cluster of differentiation (CD) 81 and stem cell antigen-1
(Sca-1), but not CD31, 34, 45, and c-kit. In vitro X-gal staining
confirmed that 100% of the MSCs from Rosa26 mice expressed
-galactosidase.
Bluescript plasmid vector containing mouse SCF was provided
by Professor T. Kunisada, Gifu University Graduate School of
Medicine.13 The SCF insert was subcloned into pCDNA3 mam-
malian expression vector. The purified plasmid was transfected
using Lipofectamine per the manufacturer’s instructions (Invitro-
gen, Carlsbad, Calif). Transfected cells were transferred to
Iscove’s modified Dulbecco’s medium with 200 g/mL G418 the
next day.
Animal Procedures
The Animal Care Committee of the University Health Network
approved all experimental procedures. Animals were sedated, in-
tubated, ventilated, and maintained with 2% isoflurane. The left
coronary artery was ligated through a thoracotomy. This typically
results in the infarction of 26.2%  1.5% of the LV at 24 hours.
For cell transplantation 300,000 cells were suspended in 15 L of
Abbreviations and Acronyms
CD  cluster of differentiation
EPC  endothelial progenitor cell
LV  left ventricle
MI  myocardial infarction
MSC mesenchymal stem cell
PECAM platelet endothelial cell adhesion molecule
SCF  stem cell factorserum-free medium and injected in 3 injections across the area
The Journal of Thoracic ansubtended by the ligated coronary artery in a predetermined series
of maneuvers that were consistent among the groups.
Laser Scanning Confocal Microscopy
Frozen optimum cutting temperature-embedded (Sakura-Finetek
Inc, Torrance, Calif) blocks (n  3 per time point) were cut into
10-mol/L sections, fixed with 20°C acetone, blocked with 5%
normal serum, incubated with 1° antibodies, and detected with
conjugated 2° antibodies. Slides were examined using an Olympus
FluoView-1000 confocal microscope (Tokyo, Japan).
Immunohistochemistry
Sections (n  3 per time point) were treated with 3% hydrogen
peroxide, blocked with normal serum, incubated with 1° anti-
CD31 antibody followed by biotinylated 2° antibody, labeled with
streptavidin-horseradish peroxidase, and developed with NovaRED
substrate (Vector Laboratories, Burlingame, Calif). For X-gal stain-
ing samples were fixed with 4% paraformaldehyde and stained
with 1 mg/mL 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
for 24 hours at 37°C. For measurement of angiogenesis, 5 random
fields in both border zones of the infarct were chosen, and the
number of large CD31-expressing structures was counted.
Endothelial Progenitor Cell Assay
Because of the confusion regarding the representative cell-surface
phenotype of EPC, we used a functional in vitro colony formation
assay to quantify EPC as described.14
Protein Quantification
Protein samples (250 g) (n  3 per time point per group) were
subjected to reducing sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. Separated proteins were transblotted onto a nitro-
cellulose membrane, blocked, and incubated overnight with 1°
SCF antibody (1:1000). The membranes were washed and incubated
with horseradish peroxidase-conjugated 2° antibody (1:3000), and
developed with a chemiluminescence kit.
Cardiac Function and Morphometry
For pressure-volume analysis (n  10 per group), 1 mL heparin-
ized saline was injected intraperitoneally 30 to 45 minutes before
the procedure to fluid-load animals. Under positive pressure ven-
tilation, a micromanometer and conductance 1.4F (Millar Instru-
ments, Inc, Houston, Tex) catheter was introduced into the LV
through the right carotid artery. Pressure-volume loops were ob-
tained during brief apnea and before and after inferior vena caval
occlusion. After evaluation, hearts and lungs were obtained and
weighed. Lungs were then dried and reweighed to estimate total
lung water (wet weight  dry weight).
Twenty-eight days after MI (n  5 per group), the hearts were
arrested and fixed at physiologic pressures. Hearts were then cut
into 1-mm sections and photographed for morphometry and
stained for histology.
Data Presentation and Statistics
Data are presented as mean  standard error of the mean with the
following abbreviations: N, noninfarcted control; M, infarcted and
media-injected control; C, infarcted and injected with MSCs; and
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tistical analysis between 2 groups was performed using a 2-tailed
t test. Multiple comparisons were performed using analysis of
variance with Bonferroni’s posttest if the overall analysis was
significant. Differences in preload recruitable stroke work and
end-systolic elastance were tested using linear regression. Survival
Figure 1. Tracking and the local impact of the implante
that 100% of MSC prepared from -galactosidase tra
(400). B, X-gal staining of the heart immediately afte
raised blue area. C, X-gal staining of the infarcted secti
significant engraftment of the cells (200). D, X-gal
surviving cells compared with day 7 is apparent (200
injected cells (arrow) in mid-myocardium immediately
as in (E) with actin labeling in green and -galacto
identifiable in the myocardium by red immunostaining
engrafted area 28 days after cell injection (arrow). -Ga
in a circumferential orientation. The adjacent
-galactosidase. H, Similar labeling as in (F) demonst
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Mesenchymal Stem Cell Implantation Does Not Induce
Cardiomyocyte Regeneration
After coronary ligation, MSC (Figure 1, A) or medium was
injected into the infarct zone. Implanted cells were identi-
lls. A, X-gal staining of the MSC in vitro demonstrating
nic animals express -galactosidase activity (blue)
jection of the MSC showing the implanted cells as a
the heart 7 days after cell implantation demonstrating
ing 28 days after implantation. Decreased number of
Hematoxylin-eosin staining demonstrating a cluster of
injection (400). F, Serial section of the same region
se labeling in red. The implanted cells (arrow) are
Similar labeling as above with nuclei in blue. Highly
sidase–expressing cells (red) are visualized arranged
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focal microscopy (Figure 1, F-I). The cells were present in
clusters in mid-myocardium after implantation (Figure 1,
C). Engraftment of -galactosidase– expressing cells was
observed to day 28 (Figure 2, D), the last time point at
which this was evaluated. Qualitatively, the number of
surviving cells decreased from day 7 to day 28, as the cells
lined circumferentially through the myocardial scar (Figure
1, C and D). However, neither immunostaining nor X-gal
staining identified -galactosidase–expressing cardiomyo-
cytes near engrafted areas in 30 border zones examined at
various time points (Figure 1, G and H). An estimated
13,350 border zone cardiomyocytes were scanned for this
analysis. Similarly, MSC implantation did not increase cell-
cycle activity in adjacent cardiomyocytes as evaluated by
expression of the Ki67 cycling antigen (Figure 1, I). In the
30 border zones at various time points that were subjected to
this analysis, the observed rate of cell-cycle activity was less
Figure 2. Cell implantation and angiogenesis (A-D). Gr
(B), myocardial angiogenesis in the border zone (C),
*P < .05. MSC, Mesenchymal stem cell; MI, myocardithan 0.1%, which was comparable to controls (Figure 1, I).
The Journal of Thoracic anMesenchymal Stem Cell Implantation Mobilizes
Endothelial Progenitor Cells and Improves
Angiogenesis
MI increased the number of peripheral EPCs that returned to
baseline by day 7 in the medium group (Figure 2, A). The
kinetic of EPC mobilization was enhanced in the MSC
group (P  .004) with a more gradual return to baseline.
Concurrently, systemic SCF levels achieved a plateau on
day 3 in the medium group, whereas in the MSC group, SCF
continued to increase to day 7 peak values, 1.3-fold higher
than in the medium group (P  .16) (Figure 2, B).
Angiogenesis was increased in the MSC group. The
number of small capillary-like structures rapidly decreased
after coronary ligation, but larger disorganized vessels be-
came apparent starting on day 7. The number of such
vessels increased 2.3-fold in the MSC group when com-
pared with controls (P  .01) on day 7 (Figure 2, C). In the
infarcted myocardium membrane isoform of SCF protein
quantifying post-MI EPC mobilization (A), serum SCF
yocardial SCF (D) (n  3 per time point per group).
farction; SCF, stem cell factor.aphs
and m
al inwas increased 2.0-fold in the MSC group (P  .04) com-
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vated SCF levels (Figure 2, D). The soluble isoform of SCF
was not observed.
Stem Cell Factor Enhancement of Mesenchymal Stem
Cells Improves Myocardial Repair After Infarction
In vitro MSC expressed SCF at low levels, and transfection
of SCF plasmid increased both membrane and soluble iso-
forms of SCF (Figure 3, A). We obtained a stably trans-
fected heterogenous cell population by selection in G418
containing medium. This cell population expressed high
levels of both isoforms of SCF in vitro (Figure 3, A). The
doubling time of the G418-selected population and the
nontransfected MSC was similar, and no morphologic
changes in cell size and shape were observed.
After induction of MI, medium, MSC, or MSC-SCF was
implanted into the infarcted area. The earliest and highest
membrane SCF expression was observed in the MSC-SCF
group (CS), followed by the MSC (C) and medium (M)
groups (Figure 3, B). The MSC-SCF group had a 3.4-fold
1310.e5 The Journal of Thoracic and Cardiovascular Surgery ● Nhigher day 3 and 3.2-fold higher day 7 myocardial SCF than
the MSC alone group (P  .05). SCF was not upregulated
in the noninjured region of the heart.
By 28 days after MI, 76.5% of animals in the medium
group, 90.6% of animals in the MSC group, and 86.3% of
animals in the MSC-SCF group were alive (log-rank P 
.11). The surviving mice underwent evaluation of diastolic
(Figure 4, A-D) and systolic cardiac function (Figure 4,
E-H). After fluid loading, end-diastolic pressures reached
26.9  0.9 mm Hg and did not differ between groups
(Figure 4, A). Changes in dP/dt min did not reach statistical
significance, but cell implantation improved tau (Figure 4, B
and C). SCF enhancement improved tau and flattened the
end-diastolic pressure volume relationship toward the non-
infarcted controls (Figure 4, D). End-systolic pressures were
on average 9.7 mm Hg higher in the cell-transplanted
groups compared with the medium group (P  .04) (Figure
4, E). Measurement of preload recruitable stroke work and
Figure 3. SCF enhancement of MSC. A, Immu-
noblot showing that MSCs express SCF in vitro
(lane 0). Transient transfection up-regulates
SCF production (lanes 1, 3, 7, and 14 denote days
after transfection), and G418 selection (lanes P0
and P5, P denotes passage number) yields a
cell population with high-level expression of
both membrane (mSCF) and soluble (sSCF) iso-
forms. Recombinant SCF (rSCF) is the positive
control. Confocal images of MSC (left and cen-
ter lower panels) and the G418-selected popu-
lation (lower right panel) probed for SCF by
immunostaining. Staining control (left panel)
showing no staining in the absence of the pri-
mary SCF antibody. The images demonstrate
low-level SCF production under basal condi-
tions, which is augmented with transfection
and G418 selection (right panel). B, Immunoblot
of infarcted segments over a time-course. MI
upregulates infarct SCF levels. MSC implanta-
tion augments this endogenous response,
which is further enhanced by the implantation
of the stably transfected MSC-SCF clone. Immu-
noblot is representative of 3 independent exper-
iments. SCF, Stem cell factor; P, passage num-
ber; N, non-infarcted control group;M,medium-
injected group; C, MSC-injected group; CS,
MSC-SCF group.end-systolic elastance demonstrated best cardiac perfor-
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Fazel et al Cardiopulmonary Support and PhysiologyFigure 4. Summary of pressure-volume analysis. Assessment of diastolic (A-D) and systolic (E-H) function (n  10 per
group). N, noninfarcted control group; M, medium-injected group; C, MSC-injected group, CS, MSC-SCF group; asterisk
(*) below the box plots denotes P< .05 comparing treated groups with group N; asterisk (*) above the box plots denotes
P< .05 comparing C and CS groups with M. Differences in end-systolic elastance and preload recruitable stroke work
between N and M, M and C, and C and CS were highly significant at P < .001 using linear regression analysis. PV,
Pressure-volume; ESV, end-systolic volume; EDV, end-diastolic volume; ESP, end-systolic pressure.
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MSC, and finally the medium-injected groups (P  .001)
(Figure 4, G and H).
Commensurate with these observations in the survivors,
heart-to-body weight ratio, indicative of cardiac hypertro-
phy, was highest in the medium and MSC groups (N, 0.4 
0.02; M, 0.6  0.13; C, 0.6  0.03 mg/g · 100; P  .05, N
vs M, and N vs C; P not significant, M vs C) and 0.8-fold
lower in the MSC-SCF group (CS, 0.5  0.01; P  .01, CS
vs M). Pulmonary congestion, as assessed by wet-to-dry
lung weights, was not different between treatment groups.
Morphometry of explanted hearts demonstrated that ven-
tricular volumes were 2.0-fold larger in the medium group
(M, 45.1  6.0 L) compared with the cell-transplanted
groups (C, 27.9  3.2; CS, 19.8  1.6 L; P  .05, M vs
C, and M vs CS). Volume of spared myocardium was not
different among the treatment groups. The surface area of
the scar was largest in the medium-injected group (M, 8.2
0.9 mm2), followed by the MSC-injected group (C, 5.7 
1.2 mm2). The scar area was significantly smaller in the
MSC-SCF group (CS, 2.8  0.5 mm2, P .001, CS vs M).
Histology of the infarcted region did not show ingrowth
of myocytes in any of the groups. A thin layer of spared
myocytes remained in the subendocardium (Figure E1).
Discussion
We made several observations in the present study: (1)
MSC implantation after MI improved cardiac function and
geometry without inducing cardiomyogenesis, (2) MSC im-
plantation enhanced EPC mobilization and induced angio-
genesis, (3) SCF, typically a cytokine associated with the
maintenance of the bone marrow c-kit stem and progenitor
cells, is markedly upregulated in infarcted hearts and further
increased after MSC implantation, and (3) increasing dys-
regulated expression of SCF by MSC augmented myocar-
dial repair.
With the use of genetic tagging we were able to assess
the fate of the injected cells. In our scanning of approxi-
mately 13,350 cardiomyocytes in the border zone of en-
grafted areas, we did not detect a single cardiomyocyte that
bore the genetic tag of the injected cells as suggested by
others.15 This was assessed by both immunostaining and
confocal microscopy as well as by X-gal staining. The dual
strategy was used to minimize the possibility of false-
positive results associated with immunofluorescent tech-
niques. Similarly, adjacent to the implanted MSC, the ob-
served rate of cardiomyocyte cell-cycle entry was less than
0.1%, ruling out the possibility that implanted cells fuse
with cardiomyocytes and induce them to enter the cell cycle
as suggested by previous studies.16,17 Furthermore, regen-
erating bands of myocardium that could have derived from
recruited stem cells were not observed by histology in the
1310.e7 The Journal of Thoracic and Cardiovascular Surgery ● Ninfarct core even when the cells overexpressed the stem cell
survival and activation factor, SCF.
Even in the absence of induced cardiomyogenesis, MSC
implantation prevented ventricular dilation and improved
load-independent indices of cardiac function. The effects of
MSC implantation included significantly improved angio-
genesis by systemic effects on EPC mobilization, and im-
proved local remodeling of the evolving infarct by prevent-
ing ventricular dilation. We believe that some of these
effects were partially mediated through increased levels of
SCF because regional overexpression of SCF by the cells
further reduced infarct surface area and improved cardiac
function. Although the MSCs are known to secrete SCF,18
the finding that MSCs secrete SCF and other cytokines after
transplantation into a fresh MI has not been demonstrated.
The current work raises the possibility that the expression of
such cytokines by the MSC may be one mechanism by
which MSC implantation improves post-MI cardiac func-
tion, independent of transdifferentiation to or fusion with
cardiomyocytes.
Myocardial SCF production is likely important through
actions on marrow-resident EPC and other precursor cells.
EPCs express c-kit, whose activation by SCF is needed for
EPC mobilization and function.19 Other bone marrow– de-
rived c-kit precursor cells have also been shown to be
important to neovascularization and cardiac repair.20,21
EPCs have been shown to increase in response to MI22,23
and to potentiate angiogenesis both by incorporating into
new vessels and by secreting angiogenic cytokines.9,24,25
This report also demonstrates that precursor cell mobiliza-
tion is greater after MSC transplantation than after coronary
ligation and medium injection. Overexpression of SCF, a
major antiapoptotic and survival factor, in the hostile infarct
is likely to improve homing, retention, and function of the
EPC and other precursor cells.26 In addition, SCF is a major
activator of c-kit mast cells, which in turn support the
proliferation and contracture of myofibroblasts.27 Mast
cells are known to infiltrate into the infarct, but their role
is unclear. The SCF axis, therefore, is intimately involved
in pathways that promote angiogenesis and formation of
myofibroblast-rich wound repair tissue, which is critically
important for progressive local remodeling and stabilization
of wounds.28
The role of SCF after MI and the mechanism of benefit
of MSCs overexpressing SCF were not evaluated in the
current study. To address the role of SCF in the injured
heart, we recently characterized the response to MI in c-kit
mutant mice (KitW/KitW-v) in which SCF binding to the c-kit
receptor does not initiate intracellular signaling. We found
that the myocardial scar expands rapidly in these mice,
resulting in 2-fold higher mortality, overt heart failure, and
marked pulmonary congestion (unpublished data). The ef-
fects were mediated by an inability of the mutant mice to
ovember 2005
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findings formed the basis for the current study. Taken to-
gether, the data indicate a critical and novel role for SCF in
the post-MI heart. We would speculate that SCF is required
for the process of wound maturation and infarct stabilization
in a dose-dependent manner.
There are limitations to the current study. Although
conversion of the MSC to cardiomyocytes was not observed
in our study, we did not assess the conversion of the
implanted MSC to other lineages and the fate of the im-
planted cells remains unknown. Likewise, cell survival was
not quantitatively assessed and the impact of SCF overpro-
duction may be through increasing MSC survival. Although
our in vitro phenotyping of the MSCs revealed that they did
not express c-kit, it is plausible that the cells begin express-
ing c-kit after implantation. Similarly, the impact of SCF
overproduction on other c-kit cells was not directly eval-
uated in the current study. Last, the prolonged culture of the
MSC before implantation may have affected the in vivo
biologic impact of the cells and limited the plasticity of the
MSC.
Conclusion
We believe that adult stem cell implantation did not regen-
erate new contractile units. Given the magnitude of the
effects on ventricular function that was observed in this and
all other previous studies, it is unlikely that the formation of
a sufficient number of new cardiomyocytes to dramatically
improve LV function could be missed. In contrast, if the
mechanism of action depends on paracrine effects on an-
giogenesis and matrix stabilization, the magnitude of these
effects could clearly be much greater than the number of
surviving transplanted MSCs. Consistent with this hypoth-
esis, the transplanted MSCs mobilized EPCs and promoted
angiogenesis, which may have increased perfusion to sur-
viving myocytes and/or enabled more rapid cardiac repair
by other cells. Through these effects the MSCs modulated
local remodeling, stabilized the infarct, and limited infarct
expansion. The SCF pathway, by indirect effects on the
formation of repair tissue through EPC and other c-kit
cells, improved the repair process and assisted in preserva-
tion of ventricular geometry. Paracrine effects of MSCs may
be one mechanism by which implantation of MSCs into a
fresh infarct prevents rapid deterioration of cardiac function.
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Discussion
Dr Georg Lutter (Kiel, Germany). Congratulations on this very
interesting work. In your study you scrutinized angiogenesis and
differentiated between the 2 study groups. Did you also analyze
and count the amount of arteriogenesis, and look for special
histologic signs of arteriogenesis, because you demonstrated your
results about the myofibril generation?
Dr Fazel. That is a very good question. Initially the way we
looked for angiogenesis was simply by identifying CD-31 or
PECAM-1–expressing structures. We weren’t looking in particu-
lar at arterioles. When we did the smooth muscle actin staining at
a later stage we saw that perhaps there could be a difference. We
did not quantify that.
Dr Robert C. Robbins (Stanford, Calif). I was a little confused
because you must have sent an abstract in that discussed the use of
wild-type and transgenic mice that were c-Kit mutants, but your
article wasn’t the same as the abstract. So what happened with the
work on the c-Kit mutant knockout?
I am not sure you wanted me to ask that. I thought it was a
beautiful abstract, and one of the things I was going to ask you is
where was your positive control with adding the stem cell factor?
You answered my question, but what happened to the knockouts?
Dr Fazel. Actually those data are very interesting. The data that
Dr Robbins is referring to are from mice that have mutation in the
c-Kit receptor. When c-Kit is completely knocked out, it results in
death in utero. There is a spontaneously c-kit mutant mouse that
has attenuated tyrosine kinase activity after binding its ligand, stem
cell factor.
The interesting thing about these mice is that after coronary
ligation, and I alluded to this in my presentation, the hearts went on
to rapid heart failure much more so than the c-Kit wild-type
controls. The mechanism, after we looked at it in detail, was a
combination of angiogenesis and an absent myofibroblast prolif-
eration response in the c-Kit mutant. That work was the basis for
1310.e9 The Journal of Thoracic and Cardiovascular Surgery ● Nthe current work, which we then tried to test the hypothesis: Is
there some sort of therapeutic intervention utility to that approach?
Dr David H. Harpole, Jr (Durham, NC). I think it is very
elegant work and very nicely done. I like the way you stepwise
worked through each of your questions with another procedure.
This is very interesting because one of the issues with cardiotox-
icity of imatinib mesylate (Gleevec) is in the patients who had
cardiotoxic chemotherapy first. With Gleevec as a blocker of c-Kit,
it kind of makes this fit together very nicely so that, to tell you the
truth, it might be interesting to look at cardiac damage in your
animals from, say, doxorubicin (Adriamycin) or something and see
whether c-Kit has a role in remodeling in those places, and that is
why giving Gleevec in those patients made them worse. That is the
first thing.
Second, have you tried using something like Gleevec as a
blocker for c-Kit as opposed to your knockout mice?
Dr Fazel. Thank you for that question because we have done
those studies following the same logic. Gleevec is a therapeutic
agent used for myoproliferative disorders. It blocks c-Kit and
platelet-derived growth factor receptors.
One of the arms in the study that Dr Robbins alluded to with the
mutant mice was to induce c-Kit inhibition pharmacologically, and
we used Gleevec in that study. The treated mice had virtually the
same phenotype as the c-kit mutant. In particular, looking at it in
more detail, there was global ventricular dilation after coronary
ligation if the animals were treated with Gleevec. When we looked
at, for example, vascular endothelial growth factor expression, we
saw that after infarction vascular endothelial growth factor would
go up in the wild type, but that it stayed low in the c-Kit mutant
and Gleevec-treated group. In addition, we looked at total cell
proliferation in the infarct and found that in wild type, again, it
goes up after infarction, in c-Kit mutant it is blunted, and with
Gleevec it is blunted. We know that most proliferating cells in an
infarct are going to be myofibroblasts. So it fit in very nicely with
those data.
Dr Yoshifumi Naka (New York, NY). I congratulate you for the
impressive work in which you seem to be suggesting that angio-
genesis is also an important factor. Have you ever looked into
hemopoietic stem cell implantation rather than the mesenchymal
stem cell?
Dr Fazel. We have not done those studies. Dr Robbins’
group did part of those studies in which the question again was
a similar one: Are these hemopoietic stem cells turning into
cardiomyocytes? In a letter to Nature, along with Dr Murray and
Dr Field, they showed that the hemopoietic stem cells, although
they may alter ventricular geometry after implantation, did not in
a large scale turn into heart muscle cells. So, again, it goes along
with the same hypothesis. We have not tried those experiments
ourselves.
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Fazel et al Cardiopulmonary Support and PhysiologyFigure E1. A, Whole heart images after in situ perfusion-fixation. The blue coronary ligature is visible and in the
same place in all hearts. Transverse section taken 1 mm below the coronary ligature (lower panel). Marked
dilation of the medium-injected group is demonstrated. B, Histologic appearance of the scar. No obvious myocyte
regeneration is apparent. Magnification: 400. N, Noninfarcted control group; M, medium-injected group; C,
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